Search Result

Results for "

LPA Receptor Activator

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Drug Isomer (1) Endogenous Metabolite (2) Interleukin Related (2) LPL Receptor (11) Mitosis (2) p38 MAPK (2) Reference Standards (2) YAP (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (8)
Oligonucleotides:	Phospholipids (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107614

1-Oleoyl lysophosphatidic acid sodium 3 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor Mitosis	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) sodium, a potent bioactive phospholipid, is a **LPA receptor** activator. 1-Oleoyl lysophosphatidic acid sodium can promote mitosis by inducing DNA synthesis. 1-Oleoyl lysophosphatidic acid sodium is also involved in normal and pathological emotional responses, including anxiety and depression .

HY-137862

1-Oleoyl lysophosphatidic acid 3 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate; 1-Oleoyl-LPA	LPL Receptor	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) is an abundant lysophosphatidic acid (LPA) species with high biological activity due to its strong affinity for the **LPA receptors*. 1-Oleoyl lysophosphatidic acid is commonly used in most laboratories as a reagent for LPA* receptor activation . 1-Oleoyl lysophosphatidic acid increases SRE-driven β-galactosidase activity .

HY-13285

Ki16425 Maximum Cited Publications 11 Publications Verification Debio 0719	LPL Receptor YAP	Neurological Disease Cancer
Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, *LPA1* and *LPA3* with K_is of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the *LPA*-induced activation of p42/p44 MAPK . Ki16425 can also inhibit *LPA*-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .

HY-157693

C18:1 Cyclic LPA	Endogenous Metabolite	Cancer
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

HY-120967

(2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98%	p38 MAPK Akt Interleukin Related	Cancer
(2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98%, Lysophosphatidic acid analogue, is a *LPA3* G-protein-coupled receptor agonist. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% can be used for the research of ovarian cancer .

HY-120967A

(2S)-OMPT	p38 MAPK Akt Interleukin Related	Cancer
(2S)-OMPT, Lysophosphatidic acid analogue, is a *LPA3* G-protein-coupled receptor agonist. (2S)-OMPT selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT can be used for the research of ovarian cancer .

HY-137862A

(Rac)-1-Oleoyl lysophosphatidic acid (Rac)-1-Oleoyl-sn-glycero-3-phosphate; (Rac)-1-Oleoyl-LPA	LPL Receptor Drug Isomer	Neurological Disease
(Rac)-1-Oleoyl lysophosphatidic acid is an isomer of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid that can activate the *LPA* receptors .

HY-N15794

AzoLPA ammonium	LPL Receptor	Neurological Disease
AzoLPA ammonium is a photoswitchable lipid that activates the Lysophosphatidic acid 1-5 (LPA1-5) receptors’ signaling .

HY-W040176

N-PTyrosine PA ammonium N-Palmitoyl-tyrosine phosphoric acid ammonium	LPL Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
N-PTyrosine PA (N-Palmitoyl-tyrosine phosphoric acid) ammonium is a lysophosphatidic acid (LPA) receptor modulator, which exhibits weak inhibitory activity against *LPA1* and partial agonist properties towards *LPA5. N-PTyrosine PA ammonium inhibits the activation* of LPA receptors and downstream responses by competing with agonists for binding sites. N-PTyrosine PA ammonium can induce morphological changes and aggregation, and also inhibit LPA-induced morphological changes through receptor desensitization caused by pre-incubation. N-PTyrosine PA ammonium can be used in the research of related diseases such as atherosclerosis and acute ischemic syndromes (e.g., unstable angina, myocardial infarction, stroke) .

HY-175084

1-Hexadecyl lysophosphatidic acid sodium 1-Hexadecyl LPA sodium; 1-Palmityl LPA sodium; LPA O-16:0 sodium	LPL Receptor	Metabolic Disease
1-Hexadecyl lysophosphatidic acid (1-Hexadecyl LPA) sodium, an ether analog of lysophosphatidic acid (LPA), is a **LPA receptor** activator .

HY-160823

2ccPA sodium 2ccPA18:1 sodium	LPL Receptor	Inflammation/Immunology Cancer
2ccPA sodium is a lysophosphatidic acid (LPA) receptor agonist. 2ccPA sodium modulates processes such as cell proliferation, migration, and apoptosis by activating LPA receptors and inhibiting autotaxin (ATX) enzyme activity. 2ccPA sodium is promising for research of cancers, inflammation, and fibrosis .

HY-W923661

1-Octadecyl lysophosphatidic acid PA(O-18:0/0:0); 1-Oleyl LPA; 1-Octadecyl LPA	LPL Receptor	Others
1-Octadecyl lysophosphatidic acid (compound 10) is a GPR92 receptor (LPA5) activator with potential flavoring effects .

HY-13285R

Ki16425 (Standard) Debio 0719 (Standard)	LPL Receptor YAP Reference Standards	Neurological Disease Cancer
Ki16425 (Standard) is the analytical standard of Ki16425. This product is intended for research and analytical applications. Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK . Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .

HY-119013

VPC32183	Endogenous Metabolite	Cardiovascular Disease
VPC32183 is a competitive antagonist of LPA1 and LPA3 receptors. The activity of VPC32183 can inhibit lipid phosphatase 1 (LPP1), thereby preventing the activation of ERK(1/2) by dioctanoic acid diglyceride (DGPP 8:0). By reducing the expression of LPP1, VPC32183 can further reduce DGPP 8:0-induced ERK(1/2) activation. The effects of VPC32183 suggest that it may have a positive regulatory function in cell signaling processes .

HY-107614R

1-Oleoyl lysophosphatidic acid sodium (Standard) 1-Oleoyl-sn-glycero-3-phosphate sodium (Standard); 1-Oleoyl-LPA sodium (Standard)	LPL Receptor Mitosis Reference Standards	Neurological Disease
1-Oleoyl lysophosphatidic acid sodium (Standard) is the analytical standard of 1-Oleoyl lysophosphatidic acid (sodium) (HY-107614). This product is intended for research and analytical applications. 1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) sodium, a potent bioactive phospholipid, is a LPA receptor activator. 1-Oleoyl lysophosphatidic acid sodium can promote mitosis by inducing DNA synthesis. 1-Oleoyl lysophosphatidic acid sodium is also involved in normal and pathological emotional responses, including anxiety and depression .

Cat. No.	Product Name	Type

HY-120967

(2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98%	Biochemical Assay Reagents
(2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98%, Lysophosphatidic acid analogue, is a *LPA3* G-protein-coupled receptor agonist. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% can be used for the research of ovarian cancer .

(2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98%

Biochemical Assay Reagents

(2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98%, Lysophosphatidic acid analogue, is a LPA3 G-protein-coupled receptor agonist. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% can be used for the research of ovarian cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N15794

AzoLPA ammonium	Lipid	LPL Receptor
AzoLPA ammonium is a photoswitchable lipid that activates the Lysophosphatidic acid 1-5 (LPA1-5) receptors’ signaling .

Cat. No.	Product Name		Classification

HY-157693

C18:1 Cyclic LPA		Phospholipids
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

HY-120967A

(2S)-OMPT		Phospholipids
(2S)-OMPT, Lysophosphatidic acid analogue, is a *LPA3* G-protein-coupled receptor agonist. (2S)-OMPT selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT can be used for the research of ovarian cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

LPA Receptor Activator

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Oligonucleotides

Natural
Products